RESCUE INHALER MARKET ANALYSIS

Market News

Recent Developments

New product launches

• On August 16, 2023, Lupin, a pharmaceutical company, announced the launch of Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, for the treatment of chronic obstructive pulmonary disease (COPD) in the U.S.
• On January 11, 2023, AstraZeneca, a pharmaceutical company, announced the launch of Airsupra rescue inhaler to reduce the risk of asthma exacerbations in adults
• In March 2021, PARI Pharma GmbH, a company focused on advanced aerosol delivery systems based on eFlow Technology, announced the authorization of the LAMIRA Nebulizer System for delivery of Insmed’s drug product ARIKAYCE (amikacin liposome inhalation suspension) in Japan. Insmed was granted approval for ARIKAYCE by Japan’s Ministry of Health, Labour and Welfare (MHLW) on March 23, 2021. The approval of ARIKAYCE in Japan follows earlier approvals in the U.S. and Europe. LAMIRA is the first drug-specific eFlow Technology nebulizer registered beyond Europe and North America

Acquisitions and partnerships

• On June 23, 2023, Kindeva Drug Delivery, a contract manufacturing and development organization (CDMO), announced the acquisition of iPharma Labs, a CDMO focused on inhaled medicine, to increase the company’s inhalation formulation outsourcing capabilities
• On May 4, 2023, Hovion, a pharmaceutical company, announced a partnership with Presspart Verwaltungs GmbH., a pharmaceutical company, for the development of Presspart’s Sunriser Capsule-based dry powder inhaler platform. The companies plan to work together to develop the Sunriser Dry Powder Inhaler, which is flexible enough to address the challenges of carrier-based and spray-dried engineered formulations
• In December 2021, Lupin, a pharmaceutical company, announced the partnership with TTP plc, a technology company, to acquire the exclusive worldwide rights from TTP plc, to develop, manufacture and commercialize inhalation products using TTP’s soft-mist inhalation technology platform. Soft-mist inhalation (SMI) technology allows for delivery of inhalation drugs from a small, portable hand-held inhaler device without the use of propellants.